Supplementary Material for: Gender Disparities in Response to Neoadjuvant Therapy for Earl

Data from the Surveillance, Epidemiology, and End Results (SEER) database from 2010 to 2022, analyzing 55,549 patients with early-stage breast cancer who received neoadjuvant therapy. The study, authored by figshare admin karger and last updated in April 2026, compares objective response rates and overall survival between 224 male and 55,325 female patients using propensity score matching.

Use Cases

• Compare objective response rates between genders based on the reported ORR percentages.
• Analyze survival outcomes among responders based on the reported median overall survival data.
• Investigate treatment response disparities within specific subgroups, such as HER2-positive patients, based on the subgroup analysis mentioned.
• Benchmark neoadjuvant therapy efficacy in male breast cancer against female cohorts based on the matched analysis.

Strengths

• Analysis is based on a large, population-based cohort of 55,549 patients.
• Uses propensity score matching to balance demographic and clinicopathological variables between groups.
• Includes specific, reported outcome metrics such as objective response rates (82.1% vs. 87.7%) and median overall survival (137 months).

Limitations

• Row count and column-level documentation are absent; field semantics must be inferred after download.
• The dataset is very small (121.9 KB), suggesting it may contain summary or supplementary material rather than the full patient-level data.
• Data may reflect geographic and temporal bias inherent to the SEER database source.

Provenance

Source

Surveillance, Epidemiology, and End Results (SEER) database.

Collection Method

Propensity score matching (1:4 ratio) was performed on identified patients.

Time Range

2010–2022

Freshness

Last updated 2026-04-20 05:55:24; freshness should be verified.

Geography

United States (inferred from SEER database coverage).